Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis: @jaccjournals.bsky.social

🥸Early TAVR led to less unplanned CV or HF hospitalization and stroke: @PhilGenereuxMD

😱 Summary

👇👇👇

🥸Two meta-analyses for older adults undergoing revascularization:

😱NSTEMI: ahajournals.org/doi/epub/10....

😱 STEMI: agsjournals.onlinelibrary.wiley.com/doi/epdf/10....

🥸We had a great journal club at American Geriatric Society with Dr Michael Nana on revacdularization in older adults

Long-Term Aspirin vs Clopidogrel After Coronary Stenting by Bleeding Risk and Procedural Complexity:
@jama.com cardiology

🥸Clopidogrel monotherapy in HOST-EXAM for patients with high bleeding risk or complex PCI

😱 Summary

👇👇👇

Coronary Physiological Indexes to Evaluate Myocardial Ischemia in Patients With Aortic Stenosis Undergoing Valve Replacement: @jaccjournals.bsky.social

🥸 Do you rely on FFR/DFR in AS patients undergoing AVR?

😱 Does AS mask coronary physiology??

👇👇👇

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia: @CircAHA

🥸 Proteomics and use of AI is the new frontier of biomarkers

😱 Summary

👇👇👇

Transcatheter Tricuspid Valve Replacement: @JACCJournals

🥸 Back from #AHA24 - a great meeting...

😱Let's summarize this for the structural community

👇👇👇

🥸 3️⃣ The composite primary endpoint (death, ICD shock, VT storm, or treated sustained VT) occurred in 50.7% of ablation patients vs. 60.6% with AADs (HR 0.75; P=0.03).

Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia: @NEJM

🥸 One of my friends said that #AHA24 brought a lot of enthusiasm back: @ahascience.bsky.social

😱 Catheter ablation for VT - it works: VANISH2

Summary

👇

Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease: @NEJM

🥸 Trials from the #AHA24 continues; bravo @ahascience.bsky.social for a very exciting meeting in Chicago!

😱 Summary

👇👇👇

🥸 1️⃣1️⃣ Subgroup analysis confirmed consistent benefits of intensive BP control regardless of age, sex, CVD history, or baseline CKD.

🥸 8️⃣ Adverse events: 36.5% (intensive) vs. 36.3% (standard). Serious adverse event rates were similar across groups.

🥸 3️⃣ After 4.2 years, primary outcomes (CV death, stroke, MI, HF hospitalization) occurred in 1.65 events/100 person-years (intensive) vs. 2.09 events/100 person-years (standard).

🥸 2️⃣ The trial enrolled 12,821 high-risk patients across 145 sites in China. Intensive treatment achieved a mean systolic BP of 121.6 mm Hg vs. 133.2 mm Hg at 1 year.

Intensive Blood-Pressure Control in Patients with Type 2 Diabetes: @NEJM

🥸 Day 3 of #AHA24 continues: Great work @ahascience.bsky.social

😱 Let's summarize BPROAD trial

👇👇👇